Branding. Licensee or its Affiliates may Commercialize the Licensed Products under the Licensed Trademarks (subject to [[Sections 3.5.3 and 5.3]3]]3]) or under separate Trademarks owned or Controlled by Licensee, provided, however, that Licensee shall not and shall cause its Affiliates and Sublicensees to not use any Trademark (other than the Licensed Trademarks) or tradename that may be confusingly similar to any Trademarks or tradenames (including the corporate or business names) of Axsome or its Affiliates.

Branding. Licensor reserves the right to display: "MarketPowerPRO Enterprise - Powered by ​" discreetly on pages within the software System.

Consultant will provide the Chief Executive Officer of the Company and the Bank with advice and project support related to community relations, branding, implementation of effective community advisory board programs and related matters as requested.

The effective term shall be one year from the Closing Date. However, the Seller and the Purchaser Guarantor shall have discussion in good faith in relation to the extension of the effective term as the current branding needs of the Licensed Company relates to the Asia market.

Coordination between Licensed Territory and Shared Territory. The Parties agree to coordinate activities, including Pricing Matters (to the extent not prohibited by Applicable Law), Distribution Matters and branding in the Licensed Territory. Consequently, SGI’s members of the JCC will provide an update regarding Commercialization activities at each meeting of the JCC.

“Second Source” means a third party, approved by ​, with whom ​ enters into an agreement under which such third party will act as a second source for ​’s customers with respect to the ​ Products, which products may be marketed and sold under the branding and marks of such third party.

Limitation. Notwithstanding the provisions of [section 9.1] above, Kx assumes no liability for # infringements arising from combinations of the Licensed Software with non-Kx software or hardware products, including any of ​’s products, # modifications to the Licensed Software made by any party other than Kx or Kx’s authorized representative or made under Kx’s direction, # use of a prior version of the Licensed Software to the extent such infringement would have been avoided by the use of the current version of the Licensed Software, provided that Kx has offered or provided such current version to ​ at no additional cost, or # trademark infringements involving any marking or branding not applied by Kx or involving any marking or branding applied at the request of ​ and not approved by Kx.

the sales and marketing cost attributed to the sale and marketing endeavours specific to the ​ Product. General sales and marketing for PearTrack, as a Company, or its general branding and corporate communications material will not be included. Specific expense line items attributable would be as follows; collateral material, printing material, travel, phone, dinners, and traditional marketing related items; and

AB Indemnity. AB shall indemnify JUPITER from, and defend JUPITER against, any and all loss, liability or expenses (including attorneys’ fees and expenses as reasonably incurred) arising out of or relating to any claim by a third party that the Product infringe upon the patent, copyright, trademark, trade secret or other intellectual property rights of any third party, except to the extent such infringement is a result of JUPITER’s “white label” branding of the Product.

Plastic USB Charger for battery assembly holds a small PCB to regulate charging. Another small PCB controls the battery function and voltage which is controlled by a clickable plastic power button seated in the stainless steel tubing that can be pressed rapidly in succession to power on/power off the battery and adjust its voltage. A small stainless steel cleaning tool is included along with cardboard for packaging and plastic blister packaging printed with instructions and branding.

“Commercialization” means all activities, whether undertaken before or after obtaining Regulatory Approvals of an MAA or NDA, relating specifically to the pre-launch, launch, promotion, marketing, branding, sales, and distribution of a Product, including: # strategic marketing, sales force detailing, advertising, medical education and liaison, reimbursement (other than Pricing Approval) and market access activities and market and Product support; and # all customer support, Product distribution, invoicing and sales activities. For clarity, Commercialization will exclude any Research, Development and Manufacturing activities. “Commercialize” has a correlative meaning.

As further described in this [Section 8.3], the tactics and strategy for the Commercialization of each Product in the Territory will be described in a comprehensive plan (each such plan, a “Joint Commercialization Plan”) that describes the pre-launch, launch and subsequent Commercialization of such Product in the Shared Territory (including anticipated activities relating to messaging, branding, Pricing Matters (to the extent not prohibited by Applicable Law), advertising, planning, marketing, sales force training and allocation, detailing, and Distribution Matters), key tactics and strategies for implementing those activities and the associated budget for such activities (each such included budget, a “Joint Commercialization Budget”).

As a member of the Board of Directors for Vet Online Supply, Samuel Berry resides in San Diego, California. A graduate from Keene State College in New Hampshire with a Bachelor of Science, and a graduate from Florida International University with his Master of Science, Mr. Berry offers VTNL over 10 years of business experience in management related to fitness and health. Mr. Berry will take charge in new business development and oversight management for all products. More specifically, Mr. Berry will assist VTNL in branding the company’s new intellectual property related to new surgical instruments and Cannabis products for future development.

Ownership and Prosecution of Product Trademarks. Regeneron shall own all right, title, and interest to all trademarks, trade dress, slogans, branding and logos and any other indicia of origin of ownership, whether registered or unregistered, including the goodwill associated specifically with each Product (collectively, “Product Trademarks”) in the Territory, and shall be solely responsible for the selection, registration, prosecution, and maintenance thereof. All costs and expenses of registering, prosecuting, and maintaining the Product Trademarks shall be borne solely by Regeneron. CytomX shall provide, at Regeneron’s sole cost and expense, assistance and documents reasonably requested by Regeneron in support of its prosecution, registration, and maintenance of the Product Trademarks.

BBTR System Development. Blackbox has customized and branded the BBTR System for providing Services to Customers utilizing BBTR Exchange Data, as mutually agreed by the Parties for marketing and sublicensing by BBTR. Except as mutually agreed by the Parties, BBTR shall be responsible for all costs associated with any further customization and branding of the BBTR System. Unless otherwise agreed by the Parties, BBTR shall pay within 30 calendar days of receipt of the invoice all additional customization costs which shall be negotiated in advance of any such customization services and invoiced by Blackbox via wire transfer per the instructions attached hereto as [Exhibit A].

employment or as otherwise authorized by RMR or the applicable RMR Company in writing, any confidential information of RMR or any RMR Company. Confidential information includes, without limitation, information regarding # the marketing, business, operational, and financial activities and/or strategies of RMR or any RMR Company # the costs, sources of supply, financial performance, projects, plans, branding, acquisition or dispositions, proposals and strategic plans of RMR or any RMR Company # any non-public financial information or practices of RMR or any RMR Company and # information and discussions concerning any past or present lawsuits, investigations, arbitrations or other pending or threatened disputes in which RMR or any RMR Company is or was a party.

professionals (to the extent not performed by sales representatives), including launch meetings; # costs of advertising and public relations with respect to a Product in the Shared Territory; # peer-to-peer activities with respect to a Product in the Shared Territory, such as ‘lunch and learns’; # promotional speaker programs with respect to a Product in the Shared Territory, including the training of such speakers; # developing, obtaining and providing training with respect to a Product in the Shared Territory, as well as training packages, promotional literature, promotional materials and other selling materials with respect to a Product in the Shared Territory; # developing and performing market research with respect to a Product in the Shared Territory and developing branding and communications plans; # conducting promotional symposia with respect to a Product in the Shared Territory; # developing reimbursement programs with respect to a Product in the Shared Territory; and # developing information specifically intended for national accounts, managed care organizations and group purchasing organizations with respect to a Product in the Shared Territory.

marketing, naming/branding, advertising, public relations, medical communications and medication adherence services for the Company’s clients, (B) the provision of clinical trials and related support services including, but not limited to, bioanalysis, biostatistics, data management, feasibility studies, global safety and pharmacovigilance, laboratory operations, medical writing, project management, protocol and case report form design, quality assurance, regulatory affairs and consulting, medical oversight, risk management, site and patient recruitment, site management, strategic planning, study monitoring and late stage services for the Company’s clients, (C) the staffing of clinical trial and/or clinical research and development personnel for the Company’s clients, and (D) the provision of consulting services including, but not limited to, brand management, business development, clinical development, commercial strategy and organizational design, product launch planning, medical affairs, pricing and market access and risk evaluation and mitigation strategy for the Company’s clients; and (ii) any other business that the Company and its Subsidiaries engage in, or that the Company and its Subsidiaries have developed definitive plans to engage in, as of the Termination Date.

"Confidential Information" means this Agreement and the Release and Waiver contained herein and any data or information, other than Trade Secrets, that is competitively sensitive to ​ or an ​ subsidiary and not generally known by the public. To the extent consistent with the foregoing definition, Confidential Information includes, without limitation: # the sales records, profit and performance records, pricing manuals, sales manuals, training manuals, selling and pricing procedures, and financing methods of ​ or any ​ subsidiary, # customer lists, the special demands of particular customers, and the current and anticipated requirements of customers for the products and services of ​ or any ​ subsidiary, # the specifications of any new products or services under development by ​ or any ​ subsidiary, # the sources of supply for integrated components and materials used for production, assembly, and packaging by ​ or any ​ subsidiary, and the quality, prices, and usage of those components and materials, and # the business plans, marketing strategies, promotional and advertising strategies, branding strategies, and internal financial statements and projections of ​ or any ​ subsidiary.